公开(公告)号：US20180037627A1

公开(公告)日：2018-02-08

申请号：US15789731

申请日：2017-10-20

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C12Q1/68 ,  C07K16/30 ,  C07K14/47 ,  C07K7/06 ,  C07K7/02 ,  A61K38/08 ,  G01N33/566 ,  C07K16/18 ,  C12N5/0783 ,  G01N33/569 ,  C12N9/64 ,  C07K16/28 ,  A61K45/06 ,  C07K14/725 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20170319675A1

公开(公告)日：2017-11-09

申请号：US15639058

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/725 ,  C12N9/64 ,  C12N5/0783 ,  A61K45/06

CPC classification number: A61K39/0011 ,  A61K38/1709 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/7051 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2502/11 ,  C12Y304/24065

Abstract: A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.

公开(公告)号：US20170290897A1

公开(公告)日：2017-10-12

申请号：US15479552

申请日：2017-04-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C12N15/115 ,  C07K14/74

CPC classification number: A61K39/0011 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K14/70539 ,  C07K16/2833 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170189509A1

公开(公告)日：2017-07-06

申请号：US15374993

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/40 ,  C07K14/725 ,  C12N9/02 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170173131A1

公开(公告)日：2017-06-22

申请号：US15374480

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/74 ,  C07K16/28

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170165339A1

公开(公告)日：2017-06-15

申请号：US15375030

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170165335A1

公开(公告)日：2017-06-15

申请号：US15073528

申请日：2016-03-17

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170056488A1

公开(公告)日：2017-03-02

申请号：US15249149

申请日：2016-08-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/113 ,  C07K16/28

CPC classification number: A61K39/0011 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3076 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57492 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170037094A1

公开(公告)日：2017-02-09

申请号：US15198471

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12P21/02 ,  G01N33/569 ,  C12Q1/68 ,  C07K7/06 ,  C07K14/725

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4738 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/30 ,  C12N2501/50 ,  C12N2501/998 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/56977 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160376314A1

公开(公告)日：2016-12-29

申请号：US15226098

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Claudia TRAUTWEIN ,  Norbert HILF ,  Steffen WALTER ,  Harpreet SINGH

IPC: C07K7/06 ,  C07K14/74 ,  A61K39/00

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.